Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer
Table 1
Response criteria and evaluation ratings used in the classification of clinical
efficacy and safety/toxicity scoring of anti-EGFR therapies for solid tumors. General
classification schemes used in review of clinical efficacy and safety, WHO criteria
[24].
General classification schemes used in review of clinical efficacy and safety:
Objective
response and tumor response were evaluated by the WHO Criteria [24].
Adverse events
(AEs) were assessed at each cycle using the common toxicity criteria (CTC).
Cardiac
failure/cardiac toxicity was graded based on the NYHA classification system.
The Cardiac Review and Evaluation Committee (CREC) evaluates cardiac dysfunction.
Factors for clinical efficacy of treatment:
In an intent-to-treat (ITT) population, in order to evaluate the overall response rate of the
individual “patient-drug interaction.”
